{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:19:35Z","timestamp":1777879175043,"version":"3.51.4"},"reference-count":31,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Fuyang Key Research and Development Plan Project"},{"name":"Clinical Medical Research Translation Special Project","award":["FYZDYF2023LCYX005"],"award-info":[{"award-number":["FYZDYF2023LCYX005"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Endocrinology"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n                    <jats:title>Aims:<\/jats:title>\n                    <jats:p>Metabolic-associated fatty liver disease (MAFLD) is closely associated with insulin resistance (IR) and systemic inflammation. Apolipoprotein A1 (ApoA1) and Apolipoprotein B (ApoB), as notable non-traditional lipid markers, have demonstrated distinct advantages in identifying risks related to metabolic syndrome and coronary atherosclerosis, yet its association with MAFLD and the mediating roles of IR\/inflammation remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      This retrospective investigation involved 1061 participants, categorized into a non-MAFLD group (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009529) and an MAFLD group (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009532). Univariate and multivariate logistic regression models, Spearman\u2019s correlation, and mediation analysis were utilized to explore the intricate associations between ApoB\/ApoA1, MAFLD, inflammation, and IR.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The MAFLD group exhibited markedly elevated levels of neutrophils\/lymphocytes, neutrophils\/platelets, systemic immune inflammation index, systemic inflammation response index, pan-immune-inflammation value and triglyceride-glucose index (TyG), TyG body mass index (TyGBMI), and metabolic score for insulin resistance (METS-IR) compared to the non-MAFLD group. Logistic regression analysis revealed that ApoB\/ApoA1, TyG, TyGBMI, and METS-IR were markedly linked to MAFLD risk. Spearman\u2019s correlation analysis identified substantial positive links between ApoB\/ApoA1 and TyG (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.45), METS-IR (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.47), and TyGBMI (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.42). Mediation analysis, adjusted for confounding variables, revealed that TyG, TyGBMI, and METS-IR mediated 70.4%, 100%, and 100% of the association between ApoB\/ApoA1 and MAFLD, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Our findings clarify the complex interrelationships between ApoB\/ApoA1, MAFLD risk, inflammation, and IR, and for the first time, demonstrate that IR may act as a key potential mediator in the link between ApoB\/ApoA1 and MAFLD, rather than systemic inflammation. This suggests that IR may serve a more prominent role than chronic systemic inflammation in the association between lipid metabolism and MAFLD risk, and intervening in IR may be more effective than anti-inflammatory therapy in blocking the progression from lipid metabolism disorders to MAFLD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20420188251378318","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T09:36:52Z","timestamp":1758015412000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Insulin resistance as potential mediator linking ApoB\/ApoA1 to MAFLD, but not inflammation"],"prefix":"10.1177","volume":"16","author":[{"given":"Mengying","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Infectious Disease, Fuyang People\u2019s Hospital, Fuyang, Anhui, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoman","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, Fuyang People\u2019s Hospital, Fuyang, Anhui, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianqian","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, Fuyang People\u2019s Hospital, Fuyang, Anhui, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Liu","sequence":"additional","affiliation":[{"name":"Physical Examination Center, Fuyang People\u2019s Hospital, Fuyang, Anhui, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3539-8325","authenticated-orcid":false,"given":"Baogui","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, Fuyang People\u2019s Hospital, No. 501 Sanqing Road, Yingzhou District, Fuyang, Anhui 236000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,9,16]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwac263"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34164"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26425"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2021.5083"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.12904"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22084156"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1231520"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-020-10094-2"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000520"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.04.015"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.2337\/dsi23-0013"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2021.0280"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1177\/03946320221137435"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1080\/21623945.2021.1970341"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1080\/17461391.2019.1571114"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1337241"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.05.044"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-025-02758-w"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2025.101419"},{"issue":"11","key":"e_1_3_5_21_2","first-page":"955","article-title":"Guideline for the prevention and treatment of metabolic dysfunction-associated fatty liver disease (Version 2024)","volume":"12","author":"Fan J-G","year":"2024","unstructured":"Fan J-G, Xu X-Y, Yang R-X, et al. Guideline for the prevention and treatment of metabolic dysfunction-associated fatty liver disease (Version 2024). J Clin Transl Hepatol 2024; 12(11): 955\u2013974.","journal-title":"J Clin Transl Hepatol"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2024.1427546"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-025-02818-1"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-024-02343-7"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-024-01646-w"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-022-01664-9"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2023.108544"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2023.02.034"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.119.315896"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2022.0099"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-075413"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2021.101847"}],"container-title":["Therapeutic Advances in Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20420188251378318","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20420188251378318","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20420188251378318","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:37:03Z","timestamp":1777592223000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20420188251378318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":31,"alternative-id":["10.1177\/20420188251378318"],"URL":"https:\/\/doi.org\/10.1177\/20420188251378318","relation":{},"ISSN":["2042-0188","2042-0196"],"issn-type":[{"value":"2042-0188","type":"print"},{"value":"2042-0196","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]},"article-number":"20420188251378318"}}